Halozyme Therapeutics’ subsidiary Halozyme Hypercon, Inc. entered into a global exclusive collaboration and license agreement with Vertex Pharmaceuticals, granting Vertex rights to use Hypercon microparticle technology for up to three drug targets. The agreement includes a $15 million upfront fee, with additional milestone payments and royalties on net sales of any products developed using the Hypercon platform.
The partnership builds on Halozyme’s recent acquisition of Elektrofi in the fall of 2025 for $750 million, which brought the Hypercon technology into Halozyme’s portfolio. Hypercon is a microparticle hyperconcentration platform that enables biologics to be formulated at higher concentrations, reducing injection volumes and facilitating patient‑delivered, subcutaneous administration. The technology complements Halozyme’s ENHANZE platform, which uses recombinant human hyaluronidase to enhance subcutaneous delivery of drugs.
For Halozyme, the deal adds a new revenue stream and extends its royalty runway. The upfront payment of $15 million is a significant cash infusion, while milestone and royalty terms are expected to generate ongoing income. Halozyme’s 2026 revenue guidance of $1.710 billion to $1.810 billion and projected royalty revenue of $1.130 billion to $1.170 billion reflect the company’s strong financial momentum, with a 37.55% revenue growth over the last twelve months and a gross profit margin of 77.78%.
Vertex stands to gain a new delivery option that could reduce injection volumes and improve patient convenience for its pipeline candidates. Vertex’s Q4 2025 earnings per share of $5.03 and the expected Q1 2026 EPS of $4.21 indicate a robust financial position, and the collaboration aligns with Vertex’s strategy to accelerate the development of next‑generation biologics.
The collaboration underscores Halozyme’s strategy to monetize its acquired technology and diversify beyond ENHANZE, while Vertex seeks to enhance its patient‑centric therapy portfolio. Helen Torley, CEO of Halozyme, said, "This collaboration with Vertex underscores the versatility and potential of our Hypercon technology to enable small‑volume, patient‑delivered next‑generation biologics." Mark Bunnage, CSO of Vertex, added, "We are pleased to add Halozyme's Hypercon drug delivery technology to our toolbox as we pursue transformative therapies for patients with serious diseases."
revised_sentiment_rating":4}]}
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.